mic evaluations

npared by disease; age
are); the majority reported
fe-year gained [LYG] or per
vention of IPD in adults

s

ectiveness of PPV-23 for the
s; incremental cost-
0 to $26,160 per LYG and

ia, cost-effectiveness ranged
LYG and from cost-saving to

ffectiveness from country to
Italy,[16] the Netherlands,[20]

ation varied from country to

variability in cost-effectiveness res
rates [14-17,20-24,26]

Relevance and strength

Structured assessment of the relevan
instrument, revealed that most studies
outcomes, and perspectives; all studie
vaccination

Vaccine efficacy assumptions

- Structured assessment showed th
vaccination against IPD available
of most of the studies
- Efficacy estimates for vaccine-rela
varied between studies, from 22%

Table 1: Sources of vaccine efficacy data

Study	Population/setting
Shapiro	Case-control study: N=1054 patients

Aggregate prote